Metrion Biosciences and Grünenthal Group extended their ion channel drug discovery collaboration

BY      |     October 26, 2020

Metrion Biosciences, a UK-based ion channel CRO, announced the extension of its long-standing ion channel drug discovery research agreement with the Grünenthal Group, a global leader in pain research.

Metrion will be providing dedicated ion channel expertise in the form of FTE based services, including electrophysiology screening of Grünenthal’s medicinal chemistry compounds.

Read more about Metrion Biosciences here.

Read more about the Grünenthal Group here.

Photo by Khwanchai Phanthong from Pexels

Comments? Questions? Suggestions?

If you have any comments, questions or suggestions concerning this article, feel free to email me at [email protected]
Alternatively, you can leave your comments on LinkedIn or Twitter.